SCHEMBL268457

SCHEMBL268457

Cc1c(C(=O)N2CCN(c3ccccc3)CC2)sc2ncn(C(=O)CN3CCC(F)(F)CC3)c(=O)c12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.54
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
MAPT P10636 1/20 0.52
THRB P10828 1/20 0.52
ALDH1A1 P00352 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
LMNA P02545 2/20 0.49
NPSR1 Q6W5P4 1/20 0.48
RAB9A P51151 1/20 0.46
NOD2 Q9HC29 1/20 0.44
TP53 P04637 1/20 0.44
KDM4E B2RXH2 1/20 0.44
POLB P06746 1/20 0.44
HTR1A P08908 1/20 0.43
HTR7 P34969 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL263680 0.87 CYP3A4 (0.59) TSHRCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL265182 0.80 CYP3A4 (0.55) TSHRCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL264488 0.79 MAPT (0.57) TSHRCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL264936 0.78 MEN1 (0.68) TSHRCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL268845 0.76 CYP3A4 (0.59) CYP3A4CYP2D6CYP2C9CYP2C19MAPT
SCHEMBL264808 0.76 MEN1 (0.62) TSHRCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL264897 0.76 MEN1 (0.62) TSHRCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL263833 0.76 CYP3A4 (0.61) TSHRCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL264526 0.76 CYP3A4 (0.65) TSHRCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL263462 0.76 MAPT (0.54) TSHRCYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133998-B2 Bicyclic pyrimidine derivatives as calcium channel blockers Zalicus Pharmaceuticals, Ltd. (CA) 2012-03-13 US disclosed
US-8133998-B2 Bicyclic pyrimidine derivatives as calcium channel blockers Zalicus Pharmaceuticals, Ltd. (CA) 2012-03-13 US disclosed
US-20080280900-A1 BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2008-11-13 US disclosed
US-20080280900-A1 BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280900-A1 BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CACNA1E, CACNA1G, RYR1 TSHR 1004/4885CYP3A4 1593/4885CYP2D6 759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.